PT-141 (Bremelanotide) in Women 65 and Older: What the Evidence Actually Shows

What Is PT-141 and Why Are Older Women Asking About It?

PT-141 is the synthetic peptide name for bremelanotide, a melanocortin-3 and melanocortin-4 receptor agonist that acts centrally on desire pathways in the brain rather than on genital blood flow. The FDA approved it in June 2019 under the brand name Vyleesi for premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD). That label is narrow. The drug does not carry an indication for postmenopausal women or for women 65 and older.

Sexual desire does not stop mattering after menopause. A 2017 AARP survey found that 51% of women 65 and older rated sex as an important part of their quality of life. Many of those women have been underserved by the two approved HSDD treatments, both of which have data almost exclusively from the reproductive years.

This creates a real clinical gap. Women over 65 frequently present to clinicians describing lost interest in sex, difficulty reaching arousal, or distressing changes in desire that began during menopause or progressed into the postmenopausal years. Bremelanotide is increasingly prescribed off-label for this group. The question you need answered honestly is: what does the evidence actually say about how the drug performs and how safe it is in women your age?

How Bremelanotide Works: Central Mechanisms and Why They Age Differently

The Melanocortin Pathway

Bremelanotide activates MC3R and MC4R receptors in the hypothalamus, including areas that regulate appetite, mood, and sexual motivation. Unlike phosphodiesterase inhibitors, it does not depend on genital arousal cues to work. The mechanism is centrally initiated: the drug increases dopamine signaling in reward circuits that drive desire before a sexual encounter begins.

This central mechanism is theoretically age-neutral. Desire circuits do not disappear after menopause. What changes is the hormonal context those circuits operate in.

How Menopause Changes the Neurobiology of Desire

Estrogen receptors are densely expressed throughout the hypothalamus and limbic system. Declining estradiol during menopause reduces serotonergic tone, alters dopamine receptor sensitivity, and lowers baseline melanocortin signaling. In practical terms, this means the neural substrate that bremelanotide is designed to stimulate is already suppressed in postmenopausal women, and the drug may need to work harder against a lower starting point.

Age-Related Pharmacokinetic Changes

Women over 65 clear drugs more slowly than younger women. Renal filtration declines roughly 1% per year after age 40, and hepatic CYP enzyme activity falls with age and with reduced lean body mass. Bremelanotide is metabolized primarily by peptide hydrolysis rather than hepatic CYP enzymes, which offers some protection against age-related drug-drug interactions. Still, older women may reach higher peak plasma concentrations than the trial population, extending the duration of nausea and the blood pressure dip that follows dosing.

Body composition also matters. Subcutaneous absorption rates vary with the amount and perfusion of adipose tissue, which shifts with age and with menopause-associated fat redistribution to the abdomen.

What the Clinical Trials Actually Show for Women 65+

The RECONNECT Trials

The key efficacy data for bremelanotide comes from two phase 3 randomized controlled trials, RECONNECT Study 1 and Study 2, published in Obstetrics and Gynecology in 2019. Together they enrolled 1,267 premenopausal women with HSDD. The mean age was approximately 38 years. Women over 65 were not enrolled.

The trials met their two co-primary endpoints: a statistically significant improvement in the Female Sexual Function Index desire domain score and a reduction in distress as measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm. The treatment difference over placebo was modest but clinically meaningful for a subset of women. Approximately 35% of treated women achieved a meaningful response defined as at least a 1.2-point increase on the FSFI desire subscale, compared with 31% of placebo-treated women in Study 1.

That 4-percentage-point difference over placebo is the number to hold in mind. For older women, we do not know whether this benefit persists, shrinks, or potentially grows given their different baseline neurobiology.

The Evidence Gap Is Real

No published randomized trial has specifically enrolled women 65 and older to test bremelanotide efficacy. The FDA clinical pharmacology review noted that geriatric pharmacokinetic studies were not conducted as part of the approval package. The prescribing information states that "clinical studies of Vyleesi did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects."

This is an honest and important disclosure. It means every clinician prescribing bremelanotide to a woman over 65 is working from extrapolation, case experience, and plausible mechanism rather than from trial data in her age group. Knowing this helps you have a more informed conversation with your prescriber about what is established versus what is assumed.

A clinically useful framework for thinking about older women and bremelanotide organizes the unknowns into three categories: efficacy (does it work as well?), safety (do the risks shift?), and context (are there better-studied alternatives?). Each deserves its own discussion.

Efficacy in Older Women: What Can Be Reasonably Expected?

Why Postmenopausal Physiology Might Reduce Response

The RECONNECT data showed that bremelanotide's effect was driven largely by its action on dopaminergic desire circuits. Postmenopausal women have lower circulating estrogen, and estrogen deficiency reduces dopamine D2 receptor density in the striatum. If the receptor substrate is less responsive, a melanocortin agonist pushing on connected pathways may generate a weaker downstream signal.

Some clinicians address this by ensuring that genitourinary syndrome of menopause (GSM) and other contributors to sexual dysfunction are treated concurrently. Vaginal dryness, dyspareunia, and reduced genital sensitivity can compound low desire in a way that a centrally acting drug alone will not resolve.

Desire Versus Arousal: The Distinction Matters More After Menopause

HSDD as a diagnostic category describes low desire specifically. Many postmenopausal women experience a different pattern: desire that emerges in response to sexual stimulation (responsive desire) rather than spontaneous desire that initiates contact. The ISSWSH consensus definitions distinguish spontaneous desire from responsive desire. Bremelanotide was studied primarily in women with deficient spontaneous desire. Its utility for women whose primary pattern is responsive desire is less certain.

This distinction matters clinically because some women over 65 who describe "no interest in sex" may actually experience desire once stimulation begins; they have responsive rather than absent desire. For those women, addressing physical barriers, relationship factors, and genital health may deliver more benefit than a pharmacological desire enhancer.

Off-Label Postmenopausal Use: What Clinicians Report

Anecdotal clinical experience from compounding pharmacy prescribers and sexual medicine specialists suggests that a subset of postmenopausal women do report subjective improvement in desire with bremelanotide. The nausea side effect, which occurs in approximately 40% of treated women in the trials, appears comparable in older women based on case series, though no controlled data support this.

Safety in Women Over 65: The Cardiovascular Question

Transient Blood Pressure Changes

The most clinically significant safety concern for older women is bremelanotide's hemodynamic effect. The drug causes a transient decrease in blood pressure averaging 6 mmHg systolic and 3 mmHg diastolic, peaking at approximately 12 minutes after injection and resolving within 12 hours. In younger, healthy women, this is generally well tolerated.

Women over 65 are more likely to be on antihypertensive medications, to have baseline cardiovascular disease, or to have orthostatic hypotension at baseline. The FDA prescribing information contraindicates bremelanotide in women with uncontrolled hypertension or cardiovascular disease. For older women, "controlled" hypertension on medication is common, and the interaction between bremelanotide's hemodynamic effect and antihypertensive agents has not been studied in this age group.

Facial Flushing, Nausea, and Fall Risk

Flushing occurs in approximately 20% of women in clinical trials and can be accompanied by a sensation of warmth and light-headedness. In an older woman with any baseline vestibular or balance concern, this combination raises a practical fall-risk question that is entirely unaddressed by the trial literature.

Nausea is the most common adverse effect. It peaks within one hour of dosing and generally resolves within four to six hours. Severe nausea leading to vomiting occurred in about 5% of trial participants. Older women who are already managing nausea from other medications, or who have reduced caloric reserve, may find this side effect more burdensome than younger women did.

Hyperpigmentation

Long-term or frequent use of melanocortin agonists can cause focal hyperpigmentation, particularly in skin folds and the face. This was reported in fewer than 1% of trial participants at approved dosing frequencies, but the trial duration was only 24 weeks. Older women with more cumulative sun exposure may have a different baseline that makes pigmentation changes more noticeable.

Drug Interactions in an Older Polypharmacy Context

Women over 65 take an average of 4.5 prescription medications daily. Bremelanotide inhibits naltrexone absorption and should not be used with naltrexone-containing products, including the combination bupropion/naltrexone (Contrave) sometimes prescribed for weight management. Clinicians prescribing bremelanotide to older women should conduct a full medication review specifically for this interaction.

Who This Drug Is Right For, and Who Should Avoid It, Framed by Life Stage

Postmenopausal Women 65 and Older: Reasonable Candidates

A woman over 65 may be a reasonable candidate for a carefully monitored off-label trial of bremelanotide if she has:

• A clear diagnosis of HSDD or female sexual interest and arousal disorder (FSIAD) with documented distress
• Well-controlled or absent cardiovascular disease
• No current use of naltrexone or bupropion/naltrexone
• Already had GSM, dyspareunia, and relationship factors assessed and addressed where possible
• Realistic expectations about a modest average benefit over placebo

Women Who Should Not Use Bremelanotide

Avoid bremelanotide if you have uncontrolled hypertension, established cardiovascular disease, a history of recent cardiac events, or if you are taking naltrexone in any formulation. Women with a history of hyperpigmentation disorders should discuss the skin risk specifically with their prescriber.

A Note on the Perimenopausal Woman Near 65

Women in late perimenopause (typically ages 48 to 56, though sometimes extending to 60) occupy a particular clinical middle ground. They may still have ovulatory cycles, even irregular ones, and retain some endogenous estrogen production. Their desire dysfunction often reflects the hormonal volatility of perimenopause rather than the fixed low-estrogen state of postmenopause. Bremelanotide addresses the central desire component but does nothing for the hormonal fluctuation itself. These women may respond differently than either the younger premenopausal trial population or a fully postmenopausal older woman.

Pregnancy, Lactation, and Contraception

Pregnancy: Contraindicated

Bremelanotide is contraindicated during pregnancy. Animal reproduction studies showed decreased fetal weight and skeletal anomalies at exposures above the clinical dose. Human pregnancy data are limited to inadvertent exposures; no controlled human reproductive safety data exist. Any woman of reproductive potential must use reliable contraception while using bremelanotide.

For the primary audience of this article, women 65 and older, confirmed menopause (12 consecutive months without a menstrual period, not explained by another cause) means pregnancy is not a concern. However, a woman who presents at 62 or 63 and has not yet had 12 consecutive amenorrheic months should not assume she cannot conceive. Contraception remains necessary until menopause is confirmed, particularly given that perimenopause can produce long inter-bleed intervals that do not equal cessation.

Lactation

Bremelanotide transfer into human breast milk has not been studied. This is clinically irrelevant for women 65 and older but would matter for any younger woman with HSDD who is breastfeeding. The prescribing information advises against use during lactation given the absence of human data.

Contraception Requirements

Any woman prescribed bremelanotide who has not confirmed menopause by the 12-month amenorrhea criterion should use a reliable contraceptive method during the treatment period. Intrauterine devices, implants, or tubal ligation are preferred over methods that require consistent daily adherence, given the cyclical nature of bremelanotide use.

Comparing Bremelanotide to Other Options for Older Women With Low Desire

Bremelanotide is not the only pharmacological option for women 65 and older experiencing HSDD or FSIAD. The comparison that matters clinically involves three other approaches.

Flibanserin (Addyi), the other FDA-approved HSDD drug, also carries a premenopausal-only label. It is a 5-HT1A agonist and 5-HT2A antagonist taken daily. Its interaction with alcohol is a meaningful clinical concern in older women who may also be using sedatives or anxiolytics.

Low-dose systemic testosterone, while not FDA-approved for women, has a more substantial evidence base for postmenopausal desire dysfunction than bremelanotide does. The ISSWSH and the Endocrine Society have issued position statements supporting off-label testosterone use in postmenopausal women with HSDD after ruling out other contributing factors. This may be a better-studied off-label option for many women over 65.

Local estrogen therapy for GSM addresses the anatomical contributors to sexual dysfunction and has Level A evidence from ACOG supporting its use in postmenopausal women. It does not treat central desire, but if dyspareunia or reduced sensation is driving avoidance, it may be more directly effective than a central agent.

Dosing Guidance for Older Women: Practical Considerations

The standard FDA-approved dose is 1.75 mg subcutaneous injection administered 45 minutes before anticipated sexual activity. No dose adjustment is specified for age in the prescribing information, because geriatric-specific pharmacokinetic data were not collected.

Given the pharmacokinetic changes associated with aging (reduced renal clearance, altered body composition, polypharmacy), a sensible clinical approach for an older woman starting bremelanotide is:

• Administer the first dose in the evening rather than before a spontaneous encounter, to allow monitoring of the blood pressure and nausea response in a low-risk setting
• Check blood pressure at 12 and 30 minutes after the first dose if the woman has any cardiovascular risk factors
• Begin with dosing no more frequently than once every 48 hours for the first month, even though the label permits once per 24 hours
• Limit to 4 doses per month initially rather than the approved maximum of 8, to observe cumulative tolerability

These are clinically conservative modifications not specified in the label but consistent with geriatric prescribing principles endorsed by the AGS Beers Criteria framework for caution with new-to-class agents in older adults.

The Bigger Picture: Sexual Health After 65 Is a Medical Issue, Not a Luxury

Low sexual desire in older women is frequently dismissed as an inevitable or unimportant consequence of aging. It is neither. Sexual function correlates with relationship satisfaction, mental health, and self-reported quality of life in women across all age groups. A 2019 study in JAMA Internal Medicine found that among women aged 65 to 80, 52% reported being sexually active, and of those, 65% reported at least one bothersome sexual problem.

Bremelanotide deserves honest evaluation as one tool in this context, not uncritical enthusiasm and not reflexive dismissal. The drug has a plausible mechanism, a real (if modest) evidence base in younger women, and a safety profile that requires more careful management in older women than the prescribing information, written for a younger trial population, might suggest.

Your prescriber should document the off-label rationale, confirm a HSDD or FSIAD diagnosis using a validated tool such as the DSDS (Decreased Sexual Desire Screener), assess your cardiovascular status, review all current medications, and establish a reassessment point at 8 to 12 weeks. If you have not noticed any subjective improvement in desire after 8 adequately spaced doses, the trial has likely failed and continuation is unlikely to help.